Key Points
DUESSELDORF, Sept 28 (Reuters) - A German court on Thursday put on hold a patent trial brought by German biotech firm CureVac (5CV.DE) against domestic rival BioNTech (22UAy.DE) over the use of mRNA technology in COVID-19 vaccines, weighing on CureVac's shares...
The Duesseldorf regional court said it suspended its proceedings until the German and the European patent offices decide on a legal challenge filed by BioNTech over the validity of CureVac's intellectual property rights...
CureVac's Germany-traded shares slumped 18% to their lowest in almost nine months, while BioNTech shares slipped 0.6%...
CureVac's efforts to develop an mRNA based COVID-19 vaccine did not succeed during the pandemic, while BioNTech generated about 17 billion euros ($17.96 billion) and 19 billion euros in annual sales in 2022 and 2021, respectively, thanks to its successful coronavirus vaccine business with partner Pfizer...
You might be interested in
Acuitas sues CureVac for credit on COVID-19 vaccine patents
14, Nov, 23Biotech company Acuitas Therapeutics has filed a lawsuit in Virginia federal court against Germany-based CureVac (5CV.DE), accusing it of failing to credit Acuitas scientists on patents related to COVID-19 vaccines.